Do analysts prefer AYTU or NCNA?

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 407.08%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AYTU or NCNA more profitable?

NuCana has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. NuCana's return on equity of -41.90% beat Aytu BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Aytu BioPharma -60.17% -69.93% -13.25% NuCana N/A -41.90% -33.69%

Do analysts recommend BFRI or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, BFRI or NCNA?

Biofrontera has higher revenue and earnings than NuCana. Biofrontera is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $41.71M 0.47 -$10.54M -$0.45 N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is BFRI or NCNA more profitable?

NuCana has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. NuCana's return on equity of -41.90% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Biofrontera -13.78% -145.81% -31.30% NuCana N/A -41.90% -33.69%

Do analysts recommend LPCN or NCNA?

Lipocine presently has a consensus price target of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipocine is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, LPCN or NCNA?

Lipocine has higher revenue and earnings than NuCana. Lipocine is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 9.20 -$9.63M -$1.79 N/A NuCana N/A N/A -$38.71M -$3.81 N/A

Is LPCN or NCNA more profitable?

NuCana has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. NuCana's return on equity of -41.90% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% NuCana N/A -41.90% -33.69%

Do analysts prefer NCNA or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NCNA or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate NCNA or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

NuCana (NCNA) Competitors

$1.34 +0.01 (+0.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.33 -0.01 (-0.75%)

As of 09/18/2026 07:30 PM Eastern

Compare

NCNA vs. AYTU, BFRI, LPCN, EGRX, and CYCN

Should you buy NuCana stock or one of its competitors? NuCana's main competitors and comparable companies include Aytu BioPharma (AYTU), Biofrontera (BFRI), Lipocine (LPCN), Eagle Pharmaceuticals (EGRX), and Cyclerion Therapeutics (CYCN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NuCana compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Aytu BioPharma has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market. Comparatively, NuCana has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

In the previous week, Aytu BioPharma had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for Aytu BioPharma and 0 mentions for NuCana. Aytu BioPharma's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Neutral
NuCana	Neutral

Aytu BioPharma has higher revenue and earnings than NuCana. Aytu BioPharma is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.34	-$13.56M	-$4.58	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

Aytu BioPharma currently has a consensus target price of $10.75, indicating a potential upside of 407.08%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. NuCana's return on equity of -41.90% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
NuCana	N/A	-41.90%	-33.69%

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aytu BioPharma and NuCana tied by winning 7 of the 14 factors compared between the two stocks.

How does NuCana compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, NuCana has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Biofrontera has higher revenue and earnings than NuCana. Biofrontera is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.47	-$10.54M	-$0.45	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

In the previous week, Biofrontera had 5 more articles in the media than NuCana. MarketBeat recorded 5 mentions for Biofrontera and 0 mentions for NuCana. Biofrontera's average media sentiment score of 0.66 beat NuCana's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Positive
NuCana	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 8.1% of Biofrontera shares are held by insiders. Comparatively, 31.2% of NuCana shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NuCana has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. NuCana's return on equity of -41.90% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
NuCana	N/A	-41.90%	-33.69%

Summary

Biofrontera beats NuCana on 8 of the 14 factors compared between the two stocks.

How does NuCana compare to Lipocine?

Lipocine (NASDAQ:LPCN) and NuCana (NASDAQ:NCNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 4.7% of Lipocine shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lipocine has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, NuCana has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Lipocine presently has a consensus price target of $15.00, suggesting a potential upside of 578.73%. Given Lipocine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Lipocine is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. NuCana's return on equity of -41.90% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
NuCana	N/A	-41.90%	-33.69%

Lipocine has higher revenue and earnings than NuCana. Lipocine is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.20	-$9.63M	-$1.79	N/A
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A

In the previous week, Lipocine had 2 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Lipocine and 0 mentions for NuCana. Lipocine's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company	Overall Sentiment
Lipocine	Neutral
NuCana	Neutral

Summary

NuCana beats Lipocine on 7 of the 13 factors compared between the two stocks.

How does NuCana compare to Eagle Pharmaceuticals?

NuCana (NASDAQ:NCNA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NuCana has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

44.0% of NuCana shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Eagle Pharmaceuticals	N/A	N/A	N/A

Eagle Pharmaceuticals has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Eagle Pharmaceuticals	$257.55M	0.06	$35.64M	$1.18	1.09

In the previous week, NuCana's average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Eagle Pharmaceuticals	Neutral

Summary

Eagle Pharmaceuticals beats NuCana on 7 of the 10 factors compared between the two stocks.

How does NuCana compare to Cyclerion Therapeutics?

NuCana (NASDAQ:NCNA) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

NuCana has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Cyclerion Therapeutics has higher revenue and earnings than NuCana. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

NuCana has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. NuCana's return on equity of -41.90% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for NuCana. NuCana's average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Cyclerion Therapeutics	Neutral

44.0% of NuCana shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cyclerion Therapeutics beats NuCana on 6 of the 11 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.58M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.35	797.25	275.49	25.40
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.17	10.53	10.46	6.33
Net Income	-$38.71M	$2.82B	$3.49B	$358.33M
7 Day Performance	1.52%	1.69%	0.59%	1.12%
1 Month Performance	-12.42%	0.24%	-1.74%	-2.39%
1 Year Performance	-63.69%	3.95%	18.13%	5.35%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	0.3016 of 5 stars	$1.34 +0.8%	N/A	-63.7%	$5.58M	N/A	N/A	11	Positive News
AYTU Aytu BioPharma	1.6471 of 5 stars	$2.00 +1.5%	$10.75 +437.5%	-13.1%	$21.14M	$66.38M	N/A	83	News Coverage Gap Up
BFRI Biofrontera	1.2234 of 5 stars	$1.24 +2.5%	N/A	+46.7%	$17.97M	$41.71M	N/A	94	News Coverage Analyst Downgrade
LPCN Lipocine	1.6418 of 5 stars	$2.22 +2.8%	$15.00 +575.7%	-23.3%	$17.81M	$1.98M	N/A	14
EGRX Eagle Pharmaceuticals	N/A	$1.29 flat	N/A	N/A	$16.69M	$257.55M	1.09	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. AYTU, BFRI, LPCN, EGRX, and CYCN

How does NuCana compare to Aytu BioPharma?

Summary

How does NuCana compare to Biofrontera?

Summary

How does NuCana compare to Lipocine?

Summary

How does NuCana compare to Eagle Pharmaceuticals?

Summary

How does NuCana compare to Cyclerion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. AYTU, BFRI, LPCN, EGRX, and CYCN

How does NuCana compare to Aytu BioPharma?

Which has more volatility & risk, AYTU or NCNA?

Does the media prefer AYTU or NCNA?

Which has higher valuation & earnings, AYTU or NCNA?

Do analysts prefer AYTU or NCNA?

Is AYTU or NCNA more profitable?

Do institutionals & insiders believe in AYTU or NCNA?

Summary

How does NuCana compare to Biofrontera?

Which has more volatility & risk, BFRI or NCNA?

Which has preferable earnings and valuation, BFRI or NCNA?

Does the media refer more to BFRI or NCNA?

Do analysts recommend BFRI or NCNA?

Do insiders and institutionals hold more shares of BFRI or NCNA?

Is BFRI or NCNA more profitable?

Summary

How does NuCana compare to Lipocine?

Do institutionals & insiders hold more shares of LPCN or NCNA?

Which has more risk and volatility, LPCN or NCNA?

Do analysts recommend LPCN or NCNA?

Is LPCN or NCNA more profitable?

Which has stronger valuation and earnings, LPCN or NCNA?

Does the media refer more to LPCN or NCNA?

Summary

How does NuCana compare to Eagle Pharmaceuticals?

Do analysts prefer NCNA or EGRX?

Which has more volatility & risk, NCNA or EGRX?

Do institutionals and insiders hold more shares of NCNA or EGRX?

Is NCNA or EGRX more profitable?

Which has higher valuation and earnings, NCNA or EGRX?

Does the media prefer NCNA or EGRX?

Summary

How does NuCana compare to Cyclerion Therapeutics?

Which has more volatility and risk, NCNA or CYCN?

Which has preferable earnings & valuation, NCNA or CYCN?

Is NCNA or CYCN more profitable?

Do analysts rate NCNA or CYCN?

Does the media favor NCNA or CYCN?

Do insiders and institutionals hold more shares of NCNA or CYCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools